🔔 Leadership Alert
Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman effective September 20, 2024, succeeding Vaidheesh Annaswamy.
based on 2 analysts
50.00%
Buy
0.00%
Hold
50.00%
Sell
Based on 2 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹810.5
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd price forecast by 2 analysts
Downside of
High
₹1050
Target
₹810.50
Low
₹571
Suven Pharmaceuticals Ltd target price ₹810.5, a slight downside of -29.2% compared to current price of ₹1179.5. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Suven Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:40.93%
Forecast
Actual
Including amortisation and stock based compensations
Suven Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:54.24%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 18.52 % |
3 Month Return | + 55.88 % |
1 Year Return | + 110.68 % |
Market Stats | |
Previous Close | ₹1,144.75 |
Open | ₹1,160.00 |
Volume | 26.36L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹29,141.32Cr |
P/E Ratio | 121.01 |
PEG Ratio | -16.78 |
Market Cap | ₹29,141.32 Cr |
P/B Ratio | 8.38 |
EPS | 11.8 |
Dividend Yield | 0 |
Sector | Pharmaceuticals |
ROE | 14.31 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
HOLD | ₹29,141.32 Cr | 115.85% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
BUY | ₹19,095.29 Cr | 32.86% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
NA | ₹7,131.04 Cr | 8.69% | 0.79 | -₹388 Cr | ₹75 Cr | |
BUY | ₹13,121.49 Cr | 37.4% | 0.68 | ₹218 Cr | ₹1,296 Cr | |
BUY | ₹25,351.51 Cr | 217.69% | 0.55 | ₹258 Cr | ₹1,375 Cr |
Organisation | Suven Pharmaceuticals Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Today's Timeline - Invalid Date
05:41 PM
-Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman, succeeding Vaidheesh Annaswamy effective September 20, 2024.
Key events for Suven Pharmaceuticals Ltd
Suven Pharmaceuticals has appointed Vivek Sharma as the new Executive Chairman, effective September 20, 2024, succeeding Vaidheesh Annaswamy, who transitions to Vice-Chair of the advisory council. Sharma brings extensive CDMO leadership experience, aiming to enhance customer connections and drive global expansion.
Suven Pharma Hits 52-Week High After USFDA Inspection - 09 Sep, 2024
Suven Pharmaceuticals' shares surged to a 52-week high following the USFDA's closure of the inspection at its subsidiary Casper Pharma's Hyderabad facility, classified as Voluntary Action Indicated (VAI). The positive developments have bolstered investor confidence despite previous revenue declines.
USFDA Inspection Results for Casper Pharma Facility - 08 Sep, 2024
The US FDA has classified the inspection of Casper Pharma's formulations manufacturing facility in Hyderabad as Voluntary Action Indicated (VAI), marking the closure of the inspection.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
In the last 3 months, SUVENPHAR stock has moved up by 55.9%
Best in 1 Year
In the last 1 year, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Profit Spike
Netprofit is up for the last 3 quarters, 46.75 Cr → 60.77 Cr (in ₹), with an average increase of 12.3% per quarter
FII Holding Up
Foreign Institutions have increased holdings from 9.54% to 9.80% in Jun 2024 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 23.5%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 50.10% of holdings in Jun 2024 quarter
MF Holding Down
Mutual Funds have decreased holdings from 15.26% to 14.78% in Jun 2024 quarter
Retail Holding Down
Retail Investor have decreased holdings from 23.10% to 22.67% in Jun 2024 quarter
Revenue Fall
Revenue is down for the last 2 quarters, 269.98 Cr → 248.85 Cr (in ₹), with an average decrease of 7.8% per quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 50.1% | 0.00 | |
Foreign Institutions | 9.8% | 2.68 | |
Mutual Funds | 14.78% | ||
Retail Investors | 22.67% | ||
Others | 2.65% | 33.19 |
Suven Pharmaceuticals Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (58.50x)
September 18, 2024
Today (121.01x)
September 18, 2024
Highest (127.70x)
September 13, 2024
Suven Pharmaceuticals Ltd’s net profit fell -49.61% since last year same period to ₹60.77Cr in the Q1 2024-2025. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 13.87% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 0.96%.
Read More about DividendsBearish
Neutral
Bullish
Suven Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Suven Pharmaceuticals Ltd (SUVENPHAR) share price today is ₹1179.5
Suven Pharmaceuticals Ltd is listed on NSE
Suven Pharmaceuticals Ltd is listed on BSE
PE Ratio of Suven Pharmaceuticals Ltd is 121.01
PE ratio = Suven Pharmaceuticals Ltd Market price per share / Suven Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 26.36L.
Today’s market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹29141.32Cr.
Suven Pharmaceuticals Ltd(SUVENPHAR | Price |
---|---|
52 Week High | ₹1257 |
52 Week Low | ₹518 |
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1179.5. It is down -6.17% from its 52 Week High price of ₹1257
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1179.5. It is up 127.70% from its 52 Week Low price of ₹518
Suven Pharmaceuticals Ltd(SUVENPHAR | Returns |
---|---|
1 Day Returns | 34.75% |
1 Month Returns | 18.52% |
3 Month Returns | 55.88% |
1 Year Returns | 110.68% |